Background: To evaluate the efficacy and toxicity of combined chemotherapy of domestic paclitaxel and vinorelbine plus cisplatin and carboplatin in the treatment of advanced non-small cell lung cancer (NSCLC).
Methods: A total of 181 initially treated patients with advanced NSCLC were enrolled in this study and treated by NP (vinorelbine plus cisplatin), TC (domestic paclitaxel plus carboplatin) and TP (domestic paclitaxel plus cisplatin). The efficacy and side effects were analysed after at least two cycles of chemotherapy.
Results: The overall response rates (CR+PR) were 42.4% in the NP arm, 40.3% in the TC arm and 43.3% in the TP arm respectively. No significant statistical difference was found among the three groups ( Chi-square= 0.108 6 , P > 0.05). The median survival times were 8.4 months, 9.4 months and 8.9 months respectively in the NP, TC and TP groups ( P > 0.05). The 1-, 2-, 3-year survival rates were 39.0%, 16.9%, 5.1% in the NP group and 41.9%, 21.0%, 6.5% in the TC group and 40.0%, 18.3%, 5.0% in the TP group respectively. No significant statistical difference was found among the three groups ( Chi-square=0.140 4, P > 0.05). The major side effects were myelosuppression, alopecia and nausea/vomiting in the three groups. There were no chemotherapy-related death among the three groups.
Conclusions: The combined regimens of NP, TC and TP are effective and well-tolerated regimens for advanced NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3779/j.issn.1009-3419.2004.03.13 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Porous SilMA Hydrogel Scaffolds Carrying Dual-Sensitive Paclitaxel Nanoparticles Promote Neuronal Differentiation for Spinal Cord Injury Repair.
Tissue Eng Regen Med
August 2024
School of Life Sciences, Bengbu Medical University, 2600 Donghai Road, Bengbu, 233030, China.
Background: In the intricate pathological milieu post-spinal cord injury (SCI), neural stem cells (NSCs) frequently differentiate into astrocytes rather than neurons, significantly limiting nerve repair. Hence, the utilization of biocompatible hydrogel scaffolds in conjunction with exogenous factors to foster the differentiation of NSCs into neurons has the potential for SCI repair.
Methods: In this study, we engineered a 3D-printed porous SilMA hydrogel scaffold (SM) supplemented with pH-/temperature-responsive paclitaxel nanoparticles (PTX-NPs).
TORCHLIGHT trial, brightening the life of more patients with advanced triple-negative breast cancer.
Transl Breast Cancer Res
September 2023
Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Article Synopsis
- Toripalimab is the first domestic PD-1 inhibitor approved in China and is developed by Shanghai Junshi Biosciences for treating advanced triple-negative breast cancer (TNBC) in a phase III trial called TORCHLIGHT, assessing its effectiveness with nab-paclitaxel.
- Nab-paclitaxel enhances drug delivery and reduces tissue damage compared to traditional chemotherapy by using albumin to improve paclitaxel's bioavailability, leading to better patient outcomes.
- The TORCHLIGHT trial showed promising results, with 95% of participants receiving first-line treatment and achieving significant improvements in both progression-free survival and overall survival, offering new hope for patients with advanced TNBC.
2-Aminoethyl Dihydrogen Phosphate (2-AEH2P) Associated with Cell Metabolism-Modulating Drugs Presents a Synergistic and Pro-Apoptotic Effect in an In Vitro Model of the Ascitic Ehrlich Tumor.
Biomedicines
January 2024
Development and Innovation Laboratory, Butantan Institute, São Paulo 05359-900, Brazil.
The progression and maintenance of cancer characteristics are associated with cellular components linked to the tumor and non-cellular components with pro-tumoral properties. Pharmacological association with antagonists of the cellular components of the tumor, such as anti- and pro-apoptotic drugs, represents a novel adjuvant strategy. In this study, the antiproliferative, pro-apoptotic, and pharmacological effects of the combination of monophosphoester 2-AEH2P with Simvastatin, Coenzyme Q10, the chemotherapeutic drug paclitaxel, and colony-stimulating factor (GM-CSF) were evaluated.
View Article and Find Full Text PDFSuccessful management of camrelizumab-induced immune-checkpoint-inhibitors-related myocarditis.
J Oncol Pharm Pract
April 2024
Department of Pathology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Introduction: Immune checkpoint inhibitors can cause immune-related toxicity in various systems, with myocarditis being the most severe and life-threatening manifestation. This report presents a case in which myocarditis developed following administration of programmed cell death protein-1 (PD-1) inhibitors therapy. We describe the diagnosis and treatment of this patient in detail.
View Article and Find Full Text PDFSynchrotron microtomography reveals insights into the degradation kinetics of bio-degradable coronary magnesium scaffolds.
Bioact Mater
February 2024
Universität des Saarlandes, Campus Homburg, 66421, Homburg, Germany.
Bioresorbable magnesium scaffolds are a promising future treatment option for coronary artery stenosis, especially for young adults. Due to the degradation of these scaffolds (<1 year), long-term device-related clinical events could be reduced compared to treatments with conventional drug eluting stents. First clinical trials indicate a return of vasomotion after one year, which may be associated with improved long-term clinical outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!